CSBio CSBio

X
[{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$363.3 million","upfrontCash":"$3.3 million","newsHeadline":"Oncodesign and Servier Reach a Key First Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Oncodesign"},{"orgOrder":0,"company":"Lysogene","sponsor":"Weizmann Institute of Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lysogene Enters Research Pact with Weizmann Institute of Science to Develop New AAV Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Lysogene"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreement involves collaboration, with the aim of developing a novel AAV gene therapy approach for neuronopathic Gaucher disease, Parkinson disease, and other diseases associated with mutations of the GBA1 gene.

            Lead Product(s): AAV gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Weizmann Institute of Science

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Servier

            Deal Size: $363.3 million Upfront Cash: $3.3 million

            Deal Type: Partnership February 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY